Revenue

Metric · Financial Performance

Displaying articles 10161–10180 of 10303 in total

Merger Closed, Lawsuit Lingers: A Warning for Healthcare Dealmakers

Read full article
BriefGlance

BlackRock's Big Bet: What a 5% Stake Means for Pharma Giant Orion

Read full article
BlackRock's Big Bet: What a 5% Stake Means for Pharma Giant Orion

Redefining Antibiotic Delivery: Inside B. Braun's New Safety System

Read full article
Redefining Antibiotic Delivery: Inside B. Braun's New Safety System

Solana's New Financial Rails: Plume Bridges TradFi Yield to DeFi

Read full article
Solana's New Financial Rails: Plume Bridges TradFi Yield to DeFi

High-Stakes Gastronomy: The Pressure Cooker of the Superyacht Kitchen

Read full article
High-Stakes Gastronomy: The Pressure Cooker of the Superyacht Kitchen

Institutional Capital Bets on Vancouver's Long-Term Rental Demand

Read full article
Institutional Capital Bets on Vancouver's Long-Term Rental Demand

The Lipman Blueprint: Data, Dominance, and Music's Newest Icons

Read full article
The Lipman Blueprint: Data, Dominance, and Music's Newest Icons

Xenon’s Epilepsy Data Signals a Market Shift Beyond Seizure Control

Read full article
Xenon’s Epilepsy Data Signals a Market Shift Beyond Seizure Control

Seegene's French Push: Building the Data Infrastructure for Health

Read full article
Seegene's French Push: Building the Data Infrastructure for Health

Prime Time for Technicians: Can a TV Spotlight Fix Aviation's Crisis?

Read full article
Prime Time for Technicians: Can a TV Spotlight Fix Aviation's Crisis?

The New Supply Chain: How Private Partnerships Control Patient Healthcare

Read full article
The New Supply Chain: How Private Partnerships Control Patient Healthcare

Biogen & Stoke Aim to Remake Dravet Treatment with Zorevunersen Data

Read full article
Biogen & Stoke Aim to Remake Dravet Treatment with Zorevunersen Data

UK Student Housing Heats Up: Balyasny's Play in the Unite-Empiric Deal

Read full article
BriefGlance

Amylyx's Second Act: New ALS Drug Aims to Rewrite its Story

Read full article
Amylyx's Second Act: New ALS Drug Aims to Rewrite its Story

Hong Kong's Gambit: How New Capital Is Fueling an I&T Renaissance

Read full article
BriefGlance

Rapport’s Epilepsy Drug Data Signals a Precision Strike on Neurology

Read full article
Rapport’s Epilepsy Drug Data Signals a Precision Strike on Neurology

Arrowstreet's Minor Trade Signals Major Stakes in AAM-Dowlais Merger

Read full article
BriefGlance

Winter's Hidden Cost: Siding Failure and Your Home's Bottom Line

Read full article
Winter's Hidden Cost: Siding Failure and Your Home's Bottom Line

Neurelis Data Reinforces VALTOCO as New Standard in Epilepsy Care

Read full article
Neurelis Data Reinforces VALTOCO as New Standard in Epilepsy Care

Trigent and WeWork India Forge Path for Mid-Market Global Hubs

Read full article
Trigent and WeWork India Forge Path for Mid-Market Global Hubs

Related topics in Financial Performance